Crinetics Pharmaceuticals Announces Director Departure, New CMO
Ticker: CRNX · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-of-directors, compensation
Related Tickers: CRNX
TL;DR
CRNX board shakeup: Milligan out, Stuppy in as CMO. Exec comp details filed.
AI Summary
On December 16, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing announced the departure of Director John F. Milligan and the appointment of Dr. R. Paul Stuppy as Chief Medical Officer. The report also includes information on compensatory arrangements for certain officers.
Why It Matters
Changes in key leadership roles and executive compensation can signal shifts in company strategy and future performance, impacting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in executive leadership and compensation can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Crinetics Pharmaceuticals, Inc. (company) — Registrant
- John F. Milligan (person) — Departing Director
- R. Paul Stuppy (person) — Appointed Chief Medical Officer
- December 16, 2024 (date) — Date of Report
FAQ
Who has departed from the Board of Directors of Crinetics Pharmaceuticals?
John F. Milligan has departed from the Board of Directors.
Who has been appointed as the new Chief Medical Officer?
Dr. R. Paul Stuppy has been appointed as the Chief Medical Officer.
What is the exact date of this 8-K filing?
The exact date of this 8-K filing is December 16, 2024.
What are the main items covered in this 8-K filing?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
What is the principal executive office address for Crinetics Pharmaceuticals?
The principal executive office address is 6055 Lusk Boulevard, San Diego, California, 92121.
Filing Stats: 1,807 words · 7 min read · ~6 pages · Grade level 13.9 · Accepted 2024-12-16 16:32:46
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select
- $500,000 — . Kalofonos' annual base salary will be $500,000, and her target annual cash incentive b
Filing Documents
- crnx-20241216.htm (8-K) — 58KB
- crnx-ex99_1.htm (EX-99.1) — 22KB
- img113038668_0.jpg (GRAPHIC) — 20KB
- 0000950170-24-136680.txt ( ) — 226KB
- crnx-20241216.xsd (EX-101.SCH) — 23KB
- crnx-20241216_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 16, 2024, the Company issued a press release announcing the appointment of Ms. Kalofonos. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 7.01, including in Exhibit 99.1 hereto, is being "furnished" and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: December 16, 2024 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)